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Complex I deficiency, the most common respiratory chain defect, is genetically heterogeneous: mutations in 
8 nuclear and 7 mitochondrial DNA genes encoding complex I subunits have been described. However, these 
genes account for disease in only a minority of complex I–deficient patients. We investigated whether there 
may be an unknown common gene by performing functional complementation analysis of cell lines from 10 
unrelated patients. Two of the patients were found to have mitochondrial DNA mutations. The other 8 repre-
sented 7 different (nuclear) complementation groups, all but 1 of which showed abnormalities of complex I 
assembly. It is thus unlikely that any one unknown gene accounts for a large proportion of complex I cases. The 
2 patients sharing a nuclear complementation group had a similar abnormal complex I assembly profile and 
were studied further by homozygosity mapping, chromosome transfers, and microarray expression analysis. 
NDUFS6, a complex I subunit gene not previously associated with complex I deficiency, was grossly underex-
pressed in the 2 patient cell lines. Both patients had homozygous mutations in this gene, one causing a splicing 
abnormality and the other a large deletion. This integrated approach to gene identification offers promise for 
identifying other unknown causes of respiratory chain disorders.
Introduction
Respiratory chain complex I deficiency is the most common dis-
order of energy generation. It has a wide range of clinical presenta-
tions, including lethal infantile mitochondrial disease, Leigh dis-
ease and other encephalopathies, cardiomyopathy, myopathy, and 
liver disease (1–3). Complex I has at least 45 subunits (4, 5), and 
mutations causing complex I deficiency have been identified in 
8 nuclear genes (NDUFS1, NDUFS2, NDUFS3, NDUFS4, NDUFS7, 
NDUFS8, NDUFV1, and NDUFV2) (6–13) and 7 mitochondrial 
DNA (mtDNA) genes (2, 14, 15). These 15 genes encode all the 
14 core complex I subunits with prokaryotic counterparts (4, 
5) plus a “supernumerary” subunit, NDUFS4, which appears 
to be involved in regulation of complex I activity by reversible 
phosphorylation (16). Fewer than 30 families have been described 
as having mutations in the 8 nuclear genes shown to cause com-
plex I deficiency, and they appear to account for only approxi-
mately 20% of patients (6). Mutations in mtDNA also appear to 
account for approximately 20% of complex I deficiency (14, 15), so 
the molecular basis remains obscure in the majority of patients.
Complex I deficiency could potentially be caused by mutations 
in any of the other approximately 30 supernumerary subunit 
genes (4, 5), in which mutations have not yet been described. In 
principle, it is possible to investigate all these genes by mutation 
analysis of a large number of patients. However, experience with 
other respiratory chain defects such as complex IV deficiency 
(17) suggests that defects may be more likely in genes involved 
in expression of mtDNA-encoded subunits or in processing and 
assembly of subunits into the mature complex. There are few 
obvious candidate genes in these categories, partly because com-
plex I is not expressed in Saccharomyces cerevisiae, and the lack of 
yeast mutants makes our understanding of complex I assembly 
relatively weak. Two assembly factors for complex I have been 
identified in Neurospora crassa (18), and the gene for the human 
homologue of one, CIA30, has been cloned, but no patients with 
CIA30 mutations have been found (19). It is likely that mutations 
in genes for as-yet-undiscovered complex I assembly, import, or 
expression factors will cause complex I deficiency, but we do not 
at present know whether there is likely to be a large or small num-
ber of unknown causes of complex I deficiency.
Complementation analysis has proven to be a powerful tool to 
characterize genetic heterogeneity of at least two other organel-
lar disorders. A common complementation group was identified 
in peroxisomal biogenesis disorders (20) and in respiratory chain 
complex IV deficiency (21, 22). In both these examples, identifica-
tion of several unrelated patients within individual complementa-
tion groups facilitated subsequent identification of the causative 
genes, PEX1 (23, 24) and SURF1 (25, 26), by somatic cell genetic, 
genomic, or candidate gene studies.
Complementation analysis has not been reported for complex I 
deficiency. We investigated whether an unrecognized gene may be a 
common cause of complex I deficiency using a strategy that involved 
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pairwise fusion of 10 patient cell lines expressing different antibiotic 
resistance genes, isolation of heterokaryons by selection with both 
antibiotics, and assay of complex I activity to determine whether it 
was rescued (complemented). DNA from the 10 patients had previ-
ously been screened by denaturing HPLC to exclude mutations in 6 
of the 8 nuclear subunit genes known to cause complex I deficiency. 
We show it is unlikely that a single major unidentified causative gene 
exists and identify a novel genetic cause of complex I deficiency.
Results
Complementation analysis. Ten patients whose complex I defi-
ciency was expressed in cultured fibroblasts (Table 1) were stud-
ied. Results of screening for mutations in the 6 nuclear com-
plex I subunit genes first shown to cause complex I deficiency 
(NDUFS1, NDUFS2, NDUFS4, NDUFS7, NDUFS8, and NDUFV1) 
and for mtDNA mutations previously associated with complex I 
deficiency were negative.
The results of all cell fusion experiments are summarized in Table 
2, divided into three categories: those with less than 30% normal 
complex I activity, i.e., not complemented; those between 30% and 
50% activity, i.e., intermediate activity; and those with greater than 
50% activity, which we considered complemented. We chose 30% as 
a cut-off figure for lack of complementation because our diagnostic 
scheme defines residual enzyme activity less than 30% in cultured 
cells as a major criterion for diagnosis of a respiratory chain defect 
(27). The 30–50% intermediate category is somewhat arbitrary; how-
ever, post hoc analysis suggests that this is reasonable. Mean com-
plex I activity in patient-patient hybrids — excluding those involv-
ing (a) 3 patients (D, E, and J) in whom an mtDNA 
cause was suggested by fusions with the ρ0 cell line, 
which contains no detectable mtDNA, (b) sibling 
pairs A and G, and (c) patients B and C, who did 
not complement — was 96%, with an SD of 25% 
(n = 20). The range (± 2 SDs) was 46–146%.
Figure 1 shows results of representative fusion 
experiments. Fusion of cell lines from 2 affected 
siblings (patients G and G2) showed no comple-
mentation, indicating a defect in the same gene, 
as expected (Figure 1A). Fusion with a control 
cell line or the ρ0 cell line (which lacks mtDNA) 
resulted in complementation, indicating that 
the defect is caused by a nuclear gene showing 
autosomal recessive inheritance (28).
Figure 1B shows results of fusions of cell lines 
from unrelated patients A and B, both with con-
sanguineous parents. The patient cell lines clearly 
complemented each other and were complement-
ed by the ρ0 cell line, indicating that they have 
defects in different genes and confirming the 
nuclear origin of these defects. Figure 1C shows 
results of fusions of cell lines from unrelated 
patients B and C. These 2 patient cell lines showed 
no complementation but were both complement-
ed by the ρ0 cell line, indicating that they have a 
defect in the same nuclear gene. Finally, the results 
of fusions of cell lines from unrelated patients D 
and E are shown in Figure 1D. These 2 patient cell 
lines showed no complementation and were not 
complemented by the ρ0 cell line, indicating that 
they both have a defect in mtDNA.
Fusions between patient cell lines and ρ0 cells resulted in complete 
restoration of complex I activity (93–156%) for 7 of the 10 patients. 
Two pairs of unrelated patient cell lines (B and C, D and E) failed to 
complement each other (15% and 18% complex I activity in fusions, 
respectively), which suggests that, for each pair, a mutation in the 
same gene was causative. For 3 patients (D, E, and J), an mtDNA eti-
ology was suggested by the absence of phenotypic rescue in hybrids 
with a ρ0 cell line that lacked mtDNA.
Mitochondrial DNA analysis. Complete mtDNA genome sequence 
analysis in patients D and E identified the same novel pathogenic 
mutation in both patients, a T10158C transition in the MTND3 
subunit gene of complex I, predicting a serine-to-proline substi-
tution, as described elsewhere (15).
Complete mtDNA sequence analysis in patient J, who was 
of Polynesian origin, identified 3 changes that may have been 
pathogenic: G10197A in the MTND3 subunit gene of complex I, 
C12239T in the MTTS2, and A15746G in the MTCYB gene. These 
changes had not been reported as polymorphic variants in the 
Mitomap database (Mitomap: A Human Mitochondrial Genome 
Database, http://www.mitomap.org/). However, screening of 
DNA samples from 21 other Polynesian patients showed that all 
3 variants were consistently present in all samples with the most 
common Polynesian haplotype (group I, haplotype 11) (29) (not 
shown). These variants are thus neutral polymorphisms, and 
mtDNA sequencing essentially excludes the presence of a patho-
genic mtDNA mutation in patient J. Patient J had intermediate 
results for complex I activity in several fusions, including that 
with the ρ0 cell line (Table 2). We postulate that patient J may 
Table 1
Clinical presentation, blood lactate, age of onset and death (if applicable), and 
residual complex I activity in primary fibroblasts of the 10 patients included in the 
complementation study
Patient M/F Clinical  Blood lactate  Age of Age at % CoI/CS in
  presentation (normal:  onset death fibroblasts 
   <2.5 mM)   (normal range:
      50–137%)
AA M LIMD 19.2 Neonatal 7 d 25
A2A F  NA PND  2
A3A M  NA PND  11
BB M LIMD 12.0 Neonatal 6 d 7
C F LIMD 6.4 Neonatal 11 d 4
C2 F LIMD 6.7 Neonatal 6 d NA
D F LIMD 6.8 6 wk 6 mo 1
E F LD 7.0 9 mo 3 yr 9 mo 14
F M LIMD 5.8 Neonatal 4 mo 14
GC M Myopathy NT Adult Alive as adults <1
G2C M  NT Adult Alive as adults <1
H M LD 11.0 Neonatal Alive at 15 yr 11
I M Persistent LA and FTT 64.3 Neonatal 2 yr 4 mo 17
J F LD-like 2.1 2 yr Alive at 13 yr 19
LIMD, lethal infantile mitochondrial disease; LD, Leigh disease; NT, not tested; LA, lactic 
acidosis; FTT, failure to thrive; PND, prenatal diagnosis, affected fetus terminated; M, male; 
F, female; NA, not available; CoI/CS, complex I activity relative to CS activity expressed as 
percentage of mean of 35 controls (2). APatient A was the first child of first-cousin parents. 
Prenatal diagnosis by enzyme analysis of cultured chorionic villi revealed complex I deficien-
cy in 2 of 4 subsequent pregnancies. Complex I deficiency was confirmed in fibroblasts after 
termination of pregnancy (A2 and A3). BConsanguineous parents. CPatients G and G2 were 
brothers with adult-onset myopathy who expressed a severe complex I defect in fibroblasts.
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have an autosomal dominant cause for complex I deficiency. She 
has a de novo translocation between chromosomes 11 and 18, 
and studies are underway to define the breakpoints and identify a 
putative causative gene. However, there are no complex I subunit 
genes or obvious candidate genes on either chromosome in the 
breakpoint regions as defined so far.
Complex I assembly. The amount and size of assembled complex I 
in patient cell lines was analyzed by Blue Native PAGE (BN-PAGE) 
immunoblotting. Complex I in the normal cell line is mainly about 
900 kDa with some super-complexes, presumably consisting of com-
plex I, complex III, and complex IV, also visible (30). Patients A, G, 
and I had almost undetectable levels of fully assembled complex I 
(∼5% of control), and patients F and H had severely reduced levels 
(∼20%). Patients D and E, with the mtDNA T10158C mutation, and 
patient J had relatively normal levels of fully assembled complex I 
(60–75%). Patients B and C, who are in the same nuclear complemen-
tation group, also had normal total amounts of complex I protein. 
However, the amount of fully assembled 900-kDa complex 
was decreased, and most of the complex (64%) was present 
in a unique complex of about 750 kDa not seen in other 
patients (Figure 2B). This is further evidence that the same 
gene is causing complex I deficiency in both patients and 
that the defect results in incomplete assembly.
Homozygosity mapping. Patient B was the only child 
of consanguineous (first cousin) Australian parents 
(Figure 3A). Patients C and C2 were the daughters of 
Turkish parents who were not known to be consanguin-
eous but were from the same small village (population 
approximately 200). There were several unexplained 
infant deaths in relatives, and consanguinity was docu-
mented in one branch of the family (Figure 3B), which 
suggests that the parents were likely to be carriers of the 
same mutant allele inherited from a common ancestor. 
Families B and C were expected to have different muta-
tions in the same gene, and each of the 3 patients was 
expected to be “homozygous by state” for polymorphic 
markers near the causative gene.
A 5-cM genome-wide scan identified 38 of 811 markers 
as being homozygous in all 3 affected individuals (Figure 
4). We focused initially on potentially the largest regions 
of homozygosity, represented by 3 adjacent homozygous markers 
on chromosome 2p and 2 adjacent homozygous markers on chro-
mosomes 2q and 21p. The 2p region contained a strong candidate 
gene, HIRIP5, potentially involved in mitochondrial iron-sulfur 
metabolism (31), but no mutations were identified in either patient 
by sequencing the 8 exons and flanking regions of HIRIP5 genomic 
DNA. Fine mapping narrowed the 13.3-Mb homozygous region on 
2p to a 5.4-Mb region between markers D2S2320 and D2S101 and 
downgraded the significance of the 2q and 21p regions by identi-
fying intervening heterozygous markers. Microcell-mediated chro-
mosome transfer (MMCT) using a hybrid rodent cell line contain-
ing human chromosome 2 as a donor failed to correct the complex 
I defect in fibroblasts from patient B. All 22 MMCT clones analyzed 
showed deficient complex I activity (<10% residual activity), which 
excluded chromosome 2 as encoding the causative gene in these 
families. We then used two independent approaches to investigate 
other homozygous regions throughout the genome.
Figure 1
Representative fusions of individual patient cell lines and of patient cell 
lines and a ρ0 (r0) cell line (lacking mtDNA) and a control cell line. Results 
are shown as complex I activity relative to the mitochondrial matrix mark-
er enzyme CS, as percentage of the mean of fusions between control 
cell lines (observed range for complex I activity relative to CS activity: 
164–169, n = 2 fusions). Error bars represent the observed range for 
all values for each cell line. N, transformed control fibroblasts; ρ0, trans-
formed 143BTK–ρ0 osteosarcoma cell line; A, B, C, D, E, and G, complex 
I–deficient transformed fibroblasts from patients A–G; others, hybrids 
between the parental cell lines as indicated. For the parental cell lines, 
the mean and observed ranges for the G418-resistant and hygromycin 
B–resistant lines combined are shown. Number of estimations for each 
cell line were: N, n = 23; ρ0, A, and C, n = 8; B, n = 11; D, n = 14; E, n = 9; 
G, n = 7; G2, n = 1; A × B, B × ρ0, A × N, C × ρ0, D × ρ0, E × N, G × G2, G × ρ0, 
and G × N, n = 2; A × ρ0, n = 3; B × C, C × N, D × N, and E × ρ0, n = 4; 
D × E, n = 6; B × N, n = 8. (A) Affected brothers G and G2 are in the 
same (nuclear) complementation group. (B) Patients A and B represent 
2 different (nuclear) complementation groups. (C) Patients B and C rep-
resent the same (nuclear) complementation group. (D) Patients D and 
E represent the same (mtDNA) complementation group.
Table 2
Summary of complementation results
 N A B C D E F G H I J ρ0
N 100 93 93 85 76 88 101 87 94 86 75 93
A  46 83 81 106 116 105 85 126 114 64 157
B    15 157 62 98 149 121 74 36 152
C     36 73 87 117 98 61 70 144
D      18 95 84 95 78 30 28
E       55 68 110 42 39 36
F        96 119 57 75 139
G        19 73 67 83 94
H          119 57 109
I           39 151
J            32
Complex I activity is expressed relative to the activity of the matrix marker enzyme 
CS (CoI/CS), as percentage of the mean of the fusions of each of the 2 parental cell 
lines for each fusion with the control cell line, e.g., for the fusion of cell lines from 
patients A and B, CoI/CS in the hybrids between patients A and B is expressed as 
the percentage of the mean of the CoI/CS in the fusions of cell lines from patient A 
with the control and patient B with the control. Boldface text: CoI/CS < 30%; under-
lined text: CoI/CS 30–50%. N, control cell line.
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Complex I subunit genes. First, we compared the chromosomal 
locations of all complex I subunit genes with the homozygous 
markers. Eight subunit genes were adjacent to homozygous mark-
ers from the 5-cM genome-wide scan, but fine mapping excluded 
four of these as being in homozygous regions. Of the remaining 4 
candidate subunit genes, NDUFV1 and NDUFS8 on chromosome 
11 had previously been excluded by mutation screening. The X 
chromosomal location of NDUFA1 meant the marker was actu-
ally hemizygous in patient B and was inconsistent with autosomal 
recessive inheritance. Thus NDUFS6 on chromosome 5 was the 
only plausible subunit gene compatible with homozygosity map-
ping, fine mapping, and previous mutation screening (Figure 4).
Transcriptome analysis. Microarray analysis was used as an alterna-
tive approach that could potentially identify genes of known or 
unknown function with abnormal expression in the patient cell 
lines, whose location could be compared with the homozygous 
markers. We used oligonucleotide microarrays representing 
17,260 genes from the Compugen 19,000 library to identify dif-
ferentially expressed genes in cell lines of patients B and C. Seven 
of the 50 genes showing the most statistically significant differen-
tial expression were downregulated in both patients, and these are 
listed in Table 3. This analysis confirmed NDUFS6 as an obvious 
candidate gene, since it was the only gene in close proximity to 
a homozygous marker from the genome-wide scan that showed 
marked downregulation in both patient cell lines when analyzed 
individually or when the data from both cell lines were pooled.
Real-time RT-PCR analysis confirmed that NDUFS6 mRNA levels 
(normalized to 18S RNA) were dramatically decreased in patients 
B and C compared with control. NDUFS6 expression was unde-
tectable in patient B, in both E6E7-transduced cells and primary 
fibroblasts, while patient C had only 3% of the control level in 
both cell lines (Table 4). By contrast, patient A, with an unknown 
nuclear gene defect, had a 52% decrease in NDUFS6 expression in 
E6E7-transduced cells and a 24% increase in primary fibroblasts. 
These modest changes are too small to be regarded as significant 
in patient A and provide further support for the specificity of 
NDUFS6 underexpression in patients B and C.
Figure 2
Immunoblot analysis and quantitation of complex-
es I and II from fibroblasts of patients A–J and 
controls (N) following separation by BN-PAGE. 
(A) Fully assembled complex I detected by an 
antibody to the 39-kDa subunit is at approxi-
mately 900 kDa. Partially assembled complex 
I detected by the same antibody is at approxi-
mately 750 kDa, and fully assembled complex II 
detected by an antibody to the 70-kDa subunit is 
at approximately 130 kDa. (B) Histogram show-
ing percentage fully (white bars) and partially 
(gray bars) assembled complex I relative to fully 
assembled complex II in primary fibroblasts. The 
error bar represents the observed range for 2 dif-
ferent control cell lines.
Figure 3
Pedigrees and haplotyping of families B and C. The symbols denote 
the following: open squares, unaffected males; open circles, unaffected 
females; open diamonds, an additional number of unaffected siblings; 
slashed symbols, unexplained infant deaths; triangle, miscarriages; 
black symbols, affected children. The homozygous regions in the pro-
bands are indicated by rectangles. The polymorphic marker shown in 
italics is not part of the original 5-cM genome-wide scan marker set. 
(A) Family B pedigree and the chromosome 5 haplotype of the affected 
child. (B) Family C pedigree and the chromosome 5 haplotype shared 
by the affected siblings.
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Mutation analysis of NDUFS6. PCR analysis of NDUFS6 cDNA 
amplified a fragment in patient C that was larger than that in con-
trol and consistently failed to amplify any fragment in patient B 
(Figure 5A). Sequencing of NDUFS6 cDNA and genomic NDUFS6 
exon 2 and adjacent DNA identified the pathogenic mutation in 
family C. Both affected siblings had a homozygous point muta-
tion (c.186+2T>A) in the splice donor site of exon 2. The ensu-
ing splicing abnormality leads to insertion of 26 bp of intronic 
material at the exon 2/exon 3 boundary of the cDNA (Figure 5B). 
This causes a frame shift and creates a premature stop codon pre-
dicted to yield a truncated protein of 71 amino acids instead of 
the wild-type 124 amino acids. The parents and an unaffected sis-
ter are heterozygous for this mutation (not shown). The abnor-
mally spliced cDNA could be amplified from RNA of cells grown 
with cycloheximide, but real-time RT-PCR showed that only 3% 
of the normal mRNA level was present in cells grown without 
cycloheximide. This implies that the major effect of this mutation 
is to cause nonsense-mediated mRNA decay.
Using an approach based on standard PCR in combination with 
long-range PCR, the NDUFS6 gene in Family B was found to har-
bor a 4.175-kb deletion that encompasses exons 3 and 4. NDUFS6 
exons 1 and 2 were successfully amplified from genomic DNA 
and sequenced in the patient with no mutations identified. How-
ever, exons 3 and 4 consistently failed to amplify. With the exon 2 
forward primer used as an anchor, reverse primers were designed 
and staggered at approximately 5-kb intervals downstream of this 
anchor. A series of long-range PCRs using each reverse primer 
separately in turn was performed, and a PCR product was gener-
ated in the patient with the reverse primer located 15 kb away. The 
resulting product, however, was only approximately 11 kb in size. 
This reverse primer was then used as an anchor, 
and new forward primers were designed at 1-kb 
intervals, commencing 4-kb upstream to ensure 
primers were located so that they spanned the 
deletion. Primers that were expected to yield an 
approximately 6.2-kb product instead generated 
an approximately 2.1-kb fragment in the patient 
(Figure 5C). This product was sequenced, and 
the deletion breakpoints were precisely identi-
fied, with the deletion starting at nucleotide 
1,865,286 and extending to nucleotide 1,869,460 
on chromosome 5 (UCSC Genome Browser, July 
2003 freeze, http://genome.ucsc.edu/cgi-bin/
hgGateway) (Figure 5D). The parents of patient 
B declined DNA testing.
We sequenced NDUFS6 cDNA and genomic 
DNA (exon 1) from 22 unrelated complex I–defi-
cient patients of different ethnicities, but no fur-
ther pathogenic mutations were identified.
Discussion
Functional complementation analysis of 10 unre-
lated patients with complex I deficiency showed 
a clear lack of complementation, implying the 
same gene is defective, in only 2 pairs of patients. 
The complex I defects in these 10 patients must 
therefore be caused by mutations in 7 different 
nuclear genes and 1 mtDNA gene. These patients 
had been screened for mutations in 6 of the 8 
nuclear-encoded complex I subunit genes known 
to cause complex I deficiency, and no mutations were found. Thus 
at least 5 of the 7 nuclear genes causing complex I deficiency in our 
patients must be novel genes. These results indicate it is unlikely 
that there is a common unidentified gene that will account for a 
substantial fraction of patients with complex I deficiency. Given 
the relatively small numbers of patients with mutations in each of 
the genes known to cause complex I deficiency and the data pre-
sented here, there is probably no single gene that accounts for more 
than about 10% of patients with complex I deficiency.
Five of the 7 nuclear complementation groups identified (rep-
resented by patients A, F, G, H, and I) showed gross deficiency of 
assembled complex I, which suggests possible defects in unidenti-
Figure 4
A chromosome map showing the location of markers that were homozygous in all 3 
affected children (as horizontal bars) in the initial 5-cM genome-wide scan. Consecu-
tive homozygous markers on chromosomes 2p (D2S2369, D2S337, and D2S2368), 2q 
(D2S2188 and D2S364), and 21p (D21S1904 and D21S1911) are highlighted by boxes. 
The approximate locations of all complex I subunit genes are shown in black text, and 
those subunit genes located adjacent to homozygous regions from the genome-wide 
scan are shown in bold italicized text. The prefix “NDU” is omitted from subunit gene 
names for clarity. The locations of the 7 most downregulated genes in both patients com-
pared with control as revealed by microarray analysis are shown by gray underlined text. 
NDUFS6 is highlighted by an ellipse, as it was the only subunit gene located adjacent to 
a homozygous region that showed significant underexpression on microarray analysis.
Table 3
Genes showing the most significant downregulation of expres-
sion in both patient B and C cell lines compared with control
Accession  Symbol Differential B statistic P value
number  expression
  (fold change)
AF026942 CIG33 –15.45 11.9 0.0000331
NM_002993 CXCL6 –11.31 8.01 0.00311
AF095844 MDA5 –7.11 11.1 0.0000875
NM_000311 PRNP –5.03 10.7 0.000146
NM_002535 OAS2 –4.89 9.57 0.000555
NM_004553 NDUFS6 –3.97 7.33 0.00633
NM_005359 MADH4 –3.01 7.17 0.00746
NDUFS6 is shown in bold. The B statistic is an estimate of the posterior 
log-odds that each gene is differentially expressed (41).
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fied assembly factors. However, it should be noted that mutations 
in at least 2 mtDNA-encoded complex I subunit genes, MTND1 and 
MTND6, cause a similar assembly defect (32, 33), and mutations 
in some nuclear-encoded subunits could potentially destabilize 
complex I assembly. Cell lines from patients D and E, with MTND3 
mutations, and patient J showed near-normal amounts of assem-
bled complex I and are thus likely to have defects that primarily 
affect complex I function, rather than assembly or stability.
Pathogenic mutations in the NDUFS6 gene have not been 
described previously. All other nuclear genes that have been shown 
to cause complex I deficiency encode subunits that are among the 
14 most conserved subunits from humans to bacteria (4, 5), with 
the exception of NDUFS4, which appears to regulate mammalian 
complex I activity by reversible phosphorylation (16).
While little is known about the role of the NDUFS6 subunit, there 
seems no doubt that the NDUFS6 mutations identified here cause 
complex I deficiency. Complementation analysis predicted that 
patients B and C would have mutations in the same gene, and they 
showed a very similar clinical phenotype and a similar abnormal 
complex I assembly profile. Of 17,260 genes studied by microarray 
expression analysis, NDUFS6 was one of the 7 most downregulated 
genes in both patient cell lines. These findings are explained by the 
large deletion and splicing abnormality identified in families B and 
C, respectively, which are expected to generate unstable mRNAs. 
Furthermore, mutations that affect production of the NDUFS4 
subunit have recently been shown to cause an assembly abnormal-
ity similar to that seen in our patients (16).
Findings from studies of complex I assembly in Neurospora 
crassa and Chlamydomonas reinhardtii mutants (34, 35) suggest 
that the membrane and peripheral arms of complex I are assem-
bled separately prior to being joined together. The size of the 
approximately 750-kDa intermediate and the fact it contains the 
39-kDa subunit suggest it represents an assembly intermediate 
of complex I corresponding to the membrane arm accumulated 
in N. crassa and C. reinhardtii mutants.
A recent study of human complex I deficient muscle biopsies 
using 2-dimensional BN-PAGE identified at least 7 different 
assembly intermediates, some of which contained both peripher-
al and membrane arm subunits (36). This suggests an alternative 
model for complex I assembly in mammals, in which the periph-
eral and membrane arms are not assembled independently. Thus 
it is unclear whether the approximately 750-kDa intermediate 
observed in patients B and C represents a simple membrane arm 
or a more complicated structure. The NDUFS4 and NDUFS6 
subunits are both located in the iron-sulfur fraction of complex I. 
It seems likely that mutations in both subunits are either pre-
venting complete assembly or destabilizing the peripheral arm 
of complex I. NDUFS6 must play an essential role in complex I 
biogenesis or stability, since the mutations identified in this 
study resulted in early and severe clinical manifestations with 
death in the neonatal period.
To date, most complex I–deficient patients identified with 
nuclear gene mutations have had “private” mutations, not found 
in other families, although some recurrent mutations in MTND 
subunits have been identified (2, 14, 15). Given the large number 
of genes causing complex I deficiency and the paucity of common 
mutations, it is important to identify methods that may aid in 
prioritizing which genes to analyze first in an individual patient. 
BN-PAGE immunoblotting using a single commercially avail-
able antibody shows some promise in this regard. It appears that 
MTND6 and MTND1 mutations cause gross deficiency of assem-
bled complex I, NDUFS4 and NDUFS6 mutations show accumula-
tion of characteristic assembly intermediates, while MTND3 and 
MTND5 mutations give a relatively normal assembly profile (15, 
16, 32, 33). Further discrimination may be possible with BN-PAGE 
using other antibodies (36) or as more experience is gained with 
techniques such as microarray analysis.
It is clear that a substantial number of genes causing complex I 
deficiency remain to be identified. These are likely to include other 
supernumerary complex I subunits and unknown assembly fac-
tors. In the study of inborn errors of metabolism, categorization 
of patients into common complementation groups provides an 
advantage for subsequent gene discovery strategies. The combina-
tion of functional complementation analysis, assembly analysis, 
homozygosity mapping, MMCT, bioinformatics, and transcrip-
tome analysis constitutes a powerful approach to the elucidation 
of the genetic causes of a heterogeneous disease such as complex 
I deficiency. Families B and C were investigated as a direct con-
sequence of the complementation and protein assembly studies, 
which led to the identification of a novel cause of complex I defi-
ciency: mutations in the NDUFS6 complex I subunit gene.
Methods
Patients. This study was approved by the Royal Children’s Hospital Ethics 
in Human Research Committee. Cell lines from 10 patients with severe 
complex I deficiency expressed in cultured fibroblasts were selected for the 
complementation study (Table 1). The clinical presentations of 3 patients 
in whom NDUFS6 mutations were subsequently identified are summarized 
below. There was 1 male baby of Anglo-Celtic origin (patient B) and two 
sibling female babies of Turkish origin (patients C and C2). All 3 were born 
at term following uneventful pregnancies and were noted to be profoundly 
hypotonic and drowsy shortly after birth. Abnormal, slowly drifting eye 
movements, rolling nystagmus, thought to indicate possible seizures, 
as well as overt seizures occurred on day 1 of life. Patients B and C had 
no spontaneous movements and minimal response to painful stimuli. 
Patient C2 made few spontaneous movements but withdrew from pain-
ful stimuli. They had weak gag and absent Moro and grasp reflexes and 
variable (diminished to brisk) deep tendon reflexes. They had a persistent 
lactic acidosis with high plasma lactate (peak values of 6 to 12 mmol/l). 
Patient C had hypoglycemia on day 1. Cerebral CT scans of patients C 
and C2 were normal. Patient C had central hypoventilation and died at 
Table 4
Quantitation of NDUFS6 expression by real-time RT-PCR in 
E6E7-transduced and primary fibroblasts
Cell Line ΔCT ± SD NDUFS6 expression
E6E7 control 9.98 ± 0.33 1.00
E6E7 patient B 25.61 ± 0.10 0.00002
E6E7 patient C 15.03 ± 0.50 0.030
E6E7 patient A 11.03 ± 0.36 0.483
Control 10.92 ± 0.54 1.00
Patient B 22.94 ± 0.33 0.00024
Patient C 16.15 ± 0.44 0.027
Patient A 10.61 ± 0.28 1.238
ΔCT represents the change in cycle of threshold fluorescence for 
NDUFS6 expression relative to the 18S RNA endogenous control for 
3–4 replicate samples. NDUFS6 gene expression in each cell line was 
normalized by assigning a value of 1 for the control cell line.
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age 11 days. Hypoventilation was noted in patient C2 on day 6, and she 
died shortly thereafter. Patient B collapsed on day 3 of life and needed 
assisted ventilation because of hypoventilation. He died on day 6 of life. 
Neuropathology revealed prominent congestion of the basal ganglia, thala-
mus, and periventricular tissue of the brain stem. Chromatolysis of many 
neurons and microvacuolation were present throughout the brain. These 
findings were similar to those seen in severe hypoxia. The lesions typical 
of Leigh disease with vascular proliferation, loosening of the neuropil, and 
preservation of neurons (37) were not seen.
Complex I enzyme and assembly assays, cell culture, and generation of hybrids. 
Cell culture and assays for complex I and citrate synthase (CS) in mito-
chondria isolated from patient cell lines, hybrids, and MMCT clones were 
performed as described (2, 37). Complex I activity was expressed relative to 
the mitochondrial matrix enzyme CS. The amount and size of assembled 
complex I were studied by BN-PAGE and immunoblotting using mito-
chondria isolated from patient cell lines and solubilized with the detergent 
dodecyl maltoside, as described previously (15, 32).
For complementation analysis, increased growth potential (due to the 
SV40T antigen) and either G418 resistance or hygromycin B resistance were 
conferred on patient cell lines and a ρ0 cell line lacking detectable mtDNA 
using the plasmids pcDNA3T or pGKHygT, as described (33). Hybrids 
were generated by fusion with polyethylene glycol and dual antibiotic selec-
tion (33). Fusions were set up at least in duplicate and in quadruplicate 
or more for fusions where initial results suggested lack of complementa-
tion or were ambiguous. Complementation was determined by assessing 
complex I activity in mitochondria isolated from the hybrids.
Microcell-mediated chromosome transfer. Primary fibroblasts from patients 
and a healthy control were transduced with a retroviral vector expressing 
the E6E7 region of type 16 human papilloma virus to extend their life-
span (25). A cell line from a panel of human-mouse monochromosomal 
hybrids (38) was used as the donor of normal human chromosome 2. This 
chromosome was transferred into the E6E7-transduced patient B cell 
line by MMCT as described previously (25), except that higher concentra-
tions of colchicine (0.1–0.4 μg/ml) were used to induce micronucleation, 
and microcells were prepared by centrifugation through a 50% Percoll 
(Amersham Biosciences) gradient at 32°C and 20,400 g in media contain-
ing cytochalasin B (20 μg/ml; Sigma-Aldrich).
Genotyping. Genome-wide scans, fine mapping, and genotyping of 
hybrids, parental cell lines, and MMCT clones were performed at the 
Australian Genome Research Facility (Melbourne, Victoria, Australia) 
using 377 and 3700 DNA sequencers (Applied Biosystems). Data were 
analyzed with GeneScan Analysis version 3.1.2 and Genotyper version 
2.1 software (Applied Biosystems).
Genome-wide scans were performed on purified DNA using the LMS2-
HD5 marker set (Applied Biosystems), which has 811 markers spread at an 
average genetic distance of 5 cM. Mapping of markers additional to those in 
Figure 5
Analysis of NDUFS6 cDNA and genomic DNA in families B and C. (A) Two percent agarose gel of NDUFS6 cDNA fragments generated by 
standard PCR. Lanes show control (Co); patient B (B); patient C (C); patient H (H); dH2O blank (Bl). PCR of NDUFS6 cDNA gave no product 
in patient B and a larger fragment than the control in patient C. (B) A representation depicting the frameshift and creation of a premature stop 
codon caused by the 26-bp insertion of intronic sequence in the proband from family C (bottom). Translation of the control sequence is also 
shown for comparison (top). The diagram shows the exon 2/exon 3 boundary, with the inserted sequence shown in bold and underlined and a 
stop codon represented by an asterisk. (C) 0.8% agarose gel of NDUFS6 fragments generated by long-range PCR using forward and reverse 
primers located 6.2 kb apart. Lanes 2–5, unrelated complex I–deficient patients. The PCR product in patient B is approximately 4 kb smaller 
than that of other samples. The approximately 2-kb fragment from lane 6 was sequenced and the deletion breakpoints elucidated. (D) Schematic 
representation of the 4.175-kb deletion, which encompasses exons 3 and 4 (shaded box) of the 14.5-kb NDUFS6 gene in the proband from 
family B. The exact homozygous deletion breakpoints are also shown with the immediate sequence before and after each breakpoint included.
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the LMS2-HD5 set was also performed. Additional markers used through-
out this study were D2S2153, D2S378, D2S2279, D2S2315, D2S1261, 
D2S2332, D2S2320, D2S402, D2S2397, D2S380, D2S1257, D2S2171, 
and D2S101 in the 2p region, D2S2173, D2S324, and D2S2261 in the 
2q region, and D21S431 in the 21p region. Markers D3S3720, D5S678, 
D9S43, D10S1133, and D11S1303 were used to characterize homozygous 
regions adjacent to complex I subunit genes including NDUFS6. Hybrids 
and parental cell lines were genotyped using an AmpFLSTR Profiler PCR 
Amplification Kit (Applied Biosystems) to confirm that the hybrids con-
tained the expected parental alleles.
Mutation analysis and DNA sequencing. Primary fibroblasts from the 10 
patients were grown for 24 hours in 100 μg/ml cycloheximide prior to 
preparation of RNA in order to minimize nonsense-mediated mRNA decay 
(39). RNA was reverse-transcribed with Multiscribe reverse transcriptase 
into cDNA using an RT-PCR kit (Applied Biosystems). cDNA was then 
screened for mutations in the NDUFS1, NDUFS2, NDUFS4, NDUFS7, 
NDUFS8, and NDUFV1 genes by denaturing HPLC, and no mutations 
were identified. The method used was essentially as described elsewhere 
(6), except that a larger number of smaller amplicons for each cDNA were 
analyzed using a Varian Prostar Helix system. Five amplicons were studied 
for NDUFV1, NDUFS1, and NDUFS2, 3 amplicons were studied for NDUFS7 
and NDUFS8, while 2 amplicons were studied for NDUFS4. All patients 
were also screened for mtDNA mutations shown previously to cause com-
plex I deficiency by sequencing of the MTTL1 gene and PCR-RFLP analy-
sis of known MTND subunit mutations (G3460A, A3796G, and T4160C 
in MTND1; C11777A and G11778A in MTND4; T12706C, G13513A and 
A13514G in MTND5; and G14459A in MTND6) (15). The entire mtDNA 
genome of patients D, E, and J was amplified, sequenced, and analyzed as 
described previously (15, 40).
Automated sequencing for NDUFS6 was performed on shrimp alka-
line phosphatase–treated PCR products (ExoSAP-IT; USB Corp.) using a 
DYEnamic ET Terminator Cycle Sequencing Kit (Amersham Biosciences). 
The sequencing reactions were purified using AutoSeq G-50 columns 
(Amersham Biosciences). Electrophoresis was performed on an Applied 
Biosystems Prism 3100 Genetic Analyzer at Applied Genetic Diagnostics, 
University of Melbourne. Sequence data were analyzed using Chromas 
(Technelysium Pty.) software version 1.51 and compared with the Refseq 
(http://www.ncbi.nlm.nih.gov/RefSeq/) NDUFS6 sequence (NM_004553).
The RefSeq NDUFS6 mRNA sequence contained only a small 5′UTR 
region, so our forward primer for PCR and sequencing of NDUFS6 cDNA 
(GAGAAGGTCACGCACACTGG) lay within exon 1, while the reverse 
primer (CCCTTTATTCAGCACCAGGA) was within the 3′ UTR. To com-
plete analysis of NDUFS6, we also amplified and sequenced exon 1 from 
genomic DNA of all patients using the primers F1 CCCAGGGCGAAATA-
AATACC and R1 ATAATCGGCTGCCACAAATC. To characterize the splic-
ing abnormality in patients C and C2, we amplified and sequenced exon 
2 and adjacent regions of NDUFS6 from genomic DNA using primers F2 
CTCCAGTTCAGACAGCACCA and R2 TTGTCAGCCTTGACAGCAAC. 
An Expand Long Template PCR kit (Roche) was used to perform long-
range PCR using system 1 buffer/reagent mix and cycling conditions. To 
generate the approximately 2.1-kb fragment by long-range PCR in patient 
B, the following primers were used: F GAACAACATAGGTGTGAACT and 
R ACCTTTTAAGCGCATGGATG. Sequencing primers were: F GAGTGT-
GCATGAAGGGGACT and R ACACATTTCCCAAGCCAAAG.
Microarrays. Gene expression profiles were obtained by competitive 
hybridization of patient versus control fibroblast RNA to arrays of the 
Compugen 19,000 human oligo library Release 1 (Adelaide Microarray 
Facility, www.microarray.adelaide.edu.au). Over 17,000 human genes 
are represented on this array, including 34 of the 38 nuclear-encoded 
complex I subunit genes, the exceptions being the NDUFA5, NDUFS7, 
NDUFV3, and NP17.3 genes. Total RNA for analysis was extracted from the 
E6E7-transduced patient and control fibroblast cell lines grown without 
cycloheximide and purified using the RNeasy Kit (Qiagen). For analysis, 
40 μg of RNA was used to create polyA+ cDNA incorporating an aadUTP 
[5-(3-aminoallyl)-2′-deoxyuridine 5′-triphosphate sodium salt; Sigma-
Aldrich]. cDNA synthesis, dye coupling, hybridization, and washing were 
performed according to protocols provided by the Adelaide Microarray 
Facility (http://www.microarray.adelaide.edu.au/protocols/) with the fol-
lowing modifications. For cDNA synthesis, SuperscriptIII (Invitrogen) 
was used for reverse transcription. Coupling of either a Cy3- or Cy5-CyDye 
Post-labelling Reactive Dye Pack (Amersham Biosciences) to the cDNA was 
performed on a QIAquick MinElute purification column (Qiagen). Slides 
were scanned using a Genepix 4000B scanner (Axon Instruments). The 
acquired microarray images were analyzed using Genepix Pro 4.0 software 
(Axon Instruments), and statistical analysis performed using limmaGUI 
(http://bioinf.wehi.edu.au/limmaGUI/). Data was normalized using Print-
tip loess normalization within R. Inter-assay variation was determined 
by label swap experiments, with a total of 4 arrays used for each patient. 
Microarray data were deposited in MIAME format at www.ebi.ac.uk/array-
express/ with accession numbers E-MEXP-118 (patient B data), E-MEXP-
119 (patient C data), and A-MEXP-70 (array design).
Real-time RT-PCR. We evaluated NDUFS6 expression by real-time RT-
PCR, using the same total RNA preparations from E6E7 transduced cells 
that were used in the microarray analyses and total RNA prepared in the 
same way from the primary fibroblast cell lines. Quantitative expression 
analysis was performed to determine relative levels of mRNA expres-
sion for NDUFS6 with the use of TaqMan Assay-on-Demand (Applied 
Biosystems) pre-designed gene expression assay on an ABI Prism 7700 
Sequence Detector (Applied Biosystems). The primer and probe sequenc-
es along with the optimal conditions for use were predetermined by the 
manufacturer. A comparative CT (cycle of threshold fluorescence) meth-
od was used with 18S RNA as an endogenous reference and calculations 
performed per manufacturer’s instructions to determine expression of 
NDUFS6 in patient cell lines relative to the control cell line. Each sample 
was run in quadruplicate.
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